165 related articles for article (PubMed ID: 38177135)
1. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity.
Yuan T; Zeng C; Liu J; Zhao C; Ge F; Li Y; Qian M; Du J; Wang W; Li Y; Liu Y; Dai X; Zhou J; Chen X; Ma S; Zhu H; He Q; Yang B
Signal Transduct Target Ther; 2024 Jan; 9(1):11. PubMed ID: 38177135
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair.
Ge F; Liu X; Zhang H; Yuan T; Zhu H; Yang B; He Q
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):533-543. PubMed ID: 37899394
[TBL] [Abstract][Full Text] [Related]
3. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation.
Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
Cell Biol Int; 2022 Jul; 46(7):1089-1097. PubMed ID: 35568970
[TBL] [Abstract][Full Text] [Related]
5. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells.
Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH
J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424
[TBL] [Abstract][Full Text] [Related]
6. Higher expression of miR-150-5p promotes tumorigenesis by suppressing LKB1 in non-small cell lung cancer.
Wu Z; Li W; Li J; Zhang Y; Zhang X; Xu Y; Hu Y; Li Q; Sun Q; Ma Z
Pathol Res Pract; 2020 Nov; 216(11):153145. PubMed ID: 32827803
[TBL] [Abstract][Full Text] [Related]
7. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
[TBL] [Abstract][Full Text] [Related]
9. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
[TBL] [Abstract][Full Text] [Related]
11. A subset of VEGFR-TKIs activates AMPK in LKB1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract][Full Text] [Related]
12. LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective.
Ciccarese F; Zulato E; Indraccolo S
Oxid Med Cell Longev; 2019; 2019():8730816. PubMed ID: 31781355
[TBL] [Abstract][Full Text] [Related]
13. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
[TBL] [Abstract][Full Text] [Related]
14. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
Yang R; Li SW; Chen Z; Zhou X; Ni W; Fu DA; Lu J; Kaye FJ; Wu L
J Natl Cancer Inst; 2019 Jul; 111(7):664-674. PubMed ID: 30423141
[TBL] [Abstract][Full Text] [Related]
15. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
[TBL] [Abstract][Full Text] [Related]
16. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
17. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
[TBL] [Abstract][Full Text] [Related]
18. The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non-small cell lung cancer.
Rodón L; Svensson RU; Wiater E; Chun MGH; Tsai WW; Eichner LJ; Shaw RJ; Montminy M
Sci Adv; 2019 Jul; 5(7):eaaw6455. PubMed ID: 31355336
[TBL] [Abstract][Full Text] [Related]
19. Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration.
Zheng X; Chi J; Zhi J; Zhang H; Yue D; Zhao J; Li D; Li Y; Gao M; Guo J
Oncogene; 2018 Jan; 37(4):502-511. PubMed ID: 28967900
[TBL] [Abstract][Full Text] [Related]
20. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
